Want to learn how to easily integrate drug data, monitor changes and construct timelines for the European and Belgian drug market? Then subscribe to our newsletter and learn from our data experts. Nice to have you on board :-)
is patience a moral duty?
Hi Reader,
“Patience is a moral duty”, my grandmother always said.
But…
standing on the train platform
sweating and gasping for air after I’ve been running like a fool
seeing my train leaving right in front of me
knowing I’ll have to wait that extra hour due to deficient railway service
I must admit I sometimes lose my patience.
Fortunately, some Spotify playlists and podcasts act as instant pain relievers in those cases.
Sadly, this is less trivial for patients with severe life threatening conditions, for whom a life saving treatment is sometimes lying ahead but just out of reach.
741 days
…will have been the waiting time for mucoviscidosis patients to get their Kaftrio treatment reimbursed in Belgium, as has it been announced for September. Way above the Belgian average for newly reimbursed drugs. Somehow, Kaftrio can be considered an exceptional case, as the negotiation process rather had the character of a telenovela, with massive media attention and Vertex even leaving the negotiation room at the end of June.
According pharma.be, in Belgium, there are on average 534 days between obtaining the market authorisation and the RIZIV/INAMI reimbursement. With those numbers, Belgium lands in 23rd place; this process is faster in almost all Western European countries. The Belgian procedure is very tedious and time-consuming, and could certainly be optimized. The “farmapact” with ongoing discussions between the pharmaceutical industry and the Belgian government will hopefully pave the way to a more lean approach. Besides, strategic factors come into play as well, as higher start prices can sometimes be obtained in other European countries, serving as a reference and delaying the initiation of a CTG/CRM procedure in our country.
And how are innovative medicines actually doing in Belgium?
Digile conducted an analysis of the 20 original innovative medicines reimbursed in Belgium since January 2022 up till now. We excluded extensions of indications. For this set, the median time from EMA authorization to RIZIV/INAMI reimbursement was 671 days. As of today, 3 out of the 20 drugs are not yet commercialised in Belgium. Ryeqo was most recently launched in August, and Kaftrio the reimbursement and commercialisation have not yet been officially announced in the Belgian prescription database SAM.
Want to see the details for specific drugs in your domain? Check out the table below.
As we are constantly monitoring changes in the drug market with our Farmanaut solutions and services, Digile can produce insightful and daily actualized reports for trends and novelties in the Belgian and European market in a glimpse.
| Discover Farmanaut |
Farmanaut integrates:
- all Belgian official drug data
- EMA EPAR data
- INAMI/RIZIV data
to produce daily actualized overviews and timelines of events, for which you can set up proactive notifications.
|
Have a nice day, Team Farmanaut >> follow us on LinkedIn |
ps: Do you have thoughts to share about this report or would you like to answer another question? Let us know in reply and we’ll see if we can help you out or make an insightful post on our LinkedIn page about it.
Hi! I'm An from Digile
Want to learn how to easily integrate drug data, monitor changes and construct timelines for the European and Belgian drug market? Then subscribe to our newsletter and learn from our data experts. Nice to have you on board :-)
Hi Reader, “We sometimes feel like a helpdesk”, the market access manager confessed, ‘but it’s mission impossible to keep track of all label extensions, changes to reimbursement criteria and upcoming launches for every possible competitor’. And she continued: “During holiday periods or with staff turnover, we get particularly stressed to keep track of all the information, stored in multiple Excel spreadsheets that need to be permanently updated and exchanged between colleagues”. Is continuity...
Hi Reader, "Hi, can we plan for a Farmaneut demo?" Farma-what? Farma-neut? As I started to visualize this new type of unhappy and somewhat grumpy medical professional, a wave of doubt made its way through my body. But soon thereafter, a warm feeling of thriving ambition made its way back to me, producing a big smile on my face. We love our customers for their enthusiasm but far underestimated their creativity. When developing market intelligence software, we felt like astronauts exploring...
Hi Reader, Do you remember the days you were buildling houses in Lego bricks? Building the house of your dreams, but then getting frustrated as you couldn't find that specific 3-dotted thin brick you needed according to plan? Of having to start it all over because you skipped that one crucial step? Or did you prefer to play around, ignoring any provided plan? And now, as an adult? Do you build your dream house brick by brick, working yourself to blood sweat and tears? Or do you consult an...